+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Diagnostics Partnering 2014-2019: Deal Trends, Players and Financials

  • ID: 2300224
  • Report
  • Region: Global
  • 1000 Pages
  • CurrentPartnering
1 of 5
Provides comprehensive understanding and unprecedented access to the diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

FEATURED COMPANIES

  • 10X Genomics
  • 7D Surgical
  • AC Immune
  • Acon Labs
  • ADS
  • Affymetrix
  • MORE
The Global Diagnostics Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.
  • Comprehensive directory of diagnostic deals since 2014
  • Diagnostic contract documents
  • Diagnostic agreement terms
  • Diagnostic agreement structure
  • Top diagnostic deals by value
  • Most active diagnostic dealmakers
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
  • Companion Diagnostics
  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • MRI
  • Ultrasound
  • X-ray
  • PET
  • SPECT
  • Angiography
  • Fluroscopy
  • Mammography
  • In vitro diagnostics
  • Molecular diagnostics
  • Prognostics
  • Theranostics
The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.

The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 2,000 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Diagnostics dealmaking.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Diagnostics deals announced by that company, as well as contract documents, where available.
  • Chapter 5 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products.

Key benefits
  • In-depth understanding of Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Diagnostics dealmakers since 2014
  • Insight into terms included in a Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 10X Genomics
  • 7D Surgical
  • AC Immune
  • Acon Labs
  • ADS
  • Affymetrix
  • MORE
1. Introduction

2. Trends in Diagnostics dealmaking
2.1. Introduction
2.2. Diagnostics partnering over the years
2.3. Most active Diagnostics dealmakers
2.4. Diagnostics partnering by deal type
2.5. Diagnostics partnering by therapy area
2.6. Deal terms for Diagnostics partnering
2.6.1 Diagnostics partnering headline values
2.6.2 Diagnostics deal upfront payments
2.6.3 Diagnostics deal milestone payments
2.6.4 Diagnostics royalty rates

3. Leading Diagnostics deals
3.1. Introduction
3.2. Top Diagnostics deals by value

4. Most active Diagnostics dealmakers
4.1. Introduction
4.2. Most active Diagnostics dealmakers
4.3. Most active Diagnostics partnering company profiles

5. Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Diagnostics contracts dealmaking directory

6. Diagnostics dealmaking by technology type

7. Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Diagnostics deals by company A-Z
Appendix 2 – Diagnostics deals by stage of development
Appendix 3 – Diagnostics deals by deal type
Appendix 4 – Diagnostics deals by therapy area
Appendix 5 – Deal type definitions

Table of Figures
Figure 1: Diagnostics partnering since 2014
Figure 2: Active Diagnostics dealmaking activity since 2014
Figure 3: Diagnostics partnering by deal type since 2014
Figure 4: Diagnostics partnering by disease type since 2014
Figure 5: Diagnostics deals with a headline value
Figure 6: Diagnostics deals with an upfront value
Figure 7: Diagnostics deals with a milestone value
Figure 8: Diagnostics deals with a royalty rate value
Figure 9: Top Diagnostics deals by value since 2014
Figure 10: Most active Diagnostics dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 2bPrecise
  • 3D Signatures
  • 3M
  • 3PrimeDx
  • 4D Molecular Therapeutics
  • 5-Diagnostics
  • 7D Surgical
  • 10X Genomics
  • 14M Genomics
  • 20/20 GeneSystems
  • 23andMe
  • 36 Strategies General Trading
  • A*STAR Agency for Science
  • Technology and Research
  • A*STAR Institute of Microelectronics (IME)
  • AAM Healthcare
  • AB Analitica
  • Abaxis
  • Abbott Laboratories
  • Abbvie
  • Abcam
  • Abcodia
  • Abramson Cancer Center
  • Acacia Research
  • Accelerate Diagnostics
  • Access BIO
  • AccuGenomics
  • Accuray
  • AccuRef Diagnostics
  • Accu Reference Medical Laboratory
  • Accuscience
  • AceCGT Life Science
  • Achaogen
  • AC Immune
  • Acon Labs
  • Acoustic MedSystems
  • Actelion
  • ACT Genomics
  • Acumen Pharmaceuticals
  • Acutus Medical
  • Adaptiiv
  • Adaptive Biotechnologies
  • ADMA Biologics
  • Admera Health
  • ADS
  • ADT Altona Diagnostic Technologies
  • Advanced Accelerator Applications
  • Advanced Animal Diagnostics
  • Advanced Biological Laboratories
  • Advanced Cell Diagnostics
  • Advanced Chemistry Development
  • Advanced Cooling Therapy
  • Advanced Genomic Solutions
  • Advanced Guidance Technologies
  • Advanced Medical German Company of Kuwait
  • Advanced Nuclear Medicine Ingredients
  • ADx Healthcare
  • Aelan Cell Technologies
  • Aerocrine
  • Aethlon Medical
  • Aetna
  • Affinium Pharmaceuticals
  • AFFiRiS
  • Affymetrix
  • Agena Bioscience
  • Agendia
  • Agfa HealthCare
  • Agilent Technologies
  • Agiomix FZ
  • Agios Pharmaceuticals
  • Agricultural Research Service
  • AIM Specialty Health
  • Aircraft Medical
  • Air Force General Hospital
  • Air Force Research Laboratory
  • AirStrip Technologies
  • AIT Laboratories
  • Akers Biosciences
  • Akili Interactive Labs
Sample list of companies, more included in the report
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2300224
Adroll
adroll